<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="28447">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01943916</url>
  </required_header>
  <id_info>
    <org_study_id>PIONEER-01</org_study_id>
    <nct_id>NCT01943916</nct_id>
    <nct_alias>NCT01937962</nct_alias>
  </id_info>
  <brief_title>The PIONEER-01 Pivotal Study of the Imagio Breast Imaging System</brief_title>
  <official_title>A Pivotal Study of Imaging With Opto-acoustics to Diagnose Breast Masses Detected by Mammography and/or Diagnostic Ultrasound: A New Evaluation Tool for Radiologists</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seno Medical Instruments Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seno Medical Instruments Inc.</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Imagio is a multi-modality device, comprised of opto-acoustic (OA) imaging co-registered
      with diagnostic grey-scale (B mode) ultrasound, that has been designed to concurrently
      collect OA images in conjunction with diagnostic grey-scale (B-mode) ultrasound.

      Imagio is expected to identify two functional hallmarks of a potential  malignancy: the
      presence of abnormal blood vessels (angiogenesis); and the relative reduction in oxygen
      content of hemoglobin.  The technology is non-invasive and does not require any contrast
      agent or radio-isotope, which is required for other modalities such as MRI or PET.

      This is a prospective, single arm, controlled, multi-center, observational study that will
      compare Imagio versus conventional diagnostic ultrasound (CDU) for the visualization of
      suspicious masses.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Case-Only, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>The primary outcome measure is the test of sensitivity and specificity of Imagio vs. standard of care ultrasound in breast lesions based on the probability of malignancy (POM).</measure>
    <time_frame>The primary endpoint is evaluated prior to biopsy for subjects with a positive-diagnostic ultrasound, and is evaluated at 12-months for subjects with a negative-diagnostic ultrasound.</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2000</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Imagio scan</arm_group_label>
    <description>Female subjects with a recently identified lesion for which a diagnostic work-up is necessary.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Imagio Scan</intervention_name>
    <arm_group_label>Imagio scan</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        A total of 2,000 female subjects who have a recently identified lesion for which further
        diagnostic work-up is necessary.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female

          -  18 years of age or older

          -  suspicious mass of breast, identified by a health care practitioner within the past
             30 days with diagnostic methodology other than conventional ultrasound.

        Exclusion Criteria:

          -  presence of a condition or impediment that may interfere with imaging.

          -  pregnant or lactating

          -  undergoing neoadjuvant therapy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>A. Thomas Stavros, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chief Medical Officer, Seno Medical Instruments, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Janet Campbell, CEO</last_name>
    <phone>(210) 576 - 1270</phone>
    <email>pioneerstudy@senomedical.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Georgetown University Hospital, Department of Radiology</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erini Makariou, MD</last_name>
    </contact>
    <investigator>
      <last_name>Erini Makariou, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic, Breast Services DDI Clinical Research</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Grobmeyer, MD</last_name>
    </contact>
    <investigator>
      <last_name>Steven Grobmeyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center, Department of Radiology and Breast Imaging</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Basak Dogan, MD</last_name>
    </contact>
    <investigator>
      <last_name>Basak Dogan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ. Texas Health Science Center at San Antontio, Breast Imaging Center at the Cancer Therapy Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ken Kist, MD</last_name>
    </contact>
    <investigator>
      <last_name>Ken Kist, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.senomedical.com</url>
    <description>Sponsor website</description>
  </link>
  <reference>
    <citation>Otto P, Kist K, Dornbluth NC, McCorvey BM, Miller T, Herzog D, Clingman B, Zalev J, Ermilov S, Oraevsky A. Improve Differentiation of Breast Tumors Using Laser Opto-Acoustic Ultrasonic Imaging System. Poster presented at: European Congress of Radiology; 2012 Mar 1-5; Vienna, Austria.</citation>
  </reference>
  <reference>
    <citation>Otto P, Kist K, Dornbluth C, Stavros T, Ulissey M, Herzog D, Clingman B, Zalev J, Lavin P, Oraevsky A. Functional Images of Hemoglobin and Blood Oxygen Saturation Co-registered with Ultrasound Provide Accurate Differentiation of Breast Tumors. Presented at: American Institute of Ultrasound in Medicine Annual Convention; 2013 Apr 6-10; New York, NY.</citation>
  </reference>
  <verification_date>September 2013</verification_date>
  <lastchanged_date>September 16, 2013</lastchanged_date>
  <firstreceived_date>September 12, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>breast imaging diagnosis</keyword>
  <keyword>breast ultrasound</keyword>
  <keyword>Imagio</keyword>
  <keyword>Seno Medical Instruments, Inc.</keyword>
  <keyword>Seno</keyword>
  <keyword>opto-acoustics</keyword>
  <keyword>OA</keyword>
  <keyword>angiogenesis</keyword>
  <keyword>blood map</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
